Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran, Inc. develops carbohydrate-based biotechnology programs focused on hypoxia, viral diseases, inflammation, metabolic health, and degenerative disease. News about BIXT commonly centers on ProLectin-M, its investigational oral antiviral candidate, including clinical study results, dose-optimization work, viral-clearance data, and regulatory-discussion updates for later-stage development.
Company updates also cover Bioxytran’s galectin-targeting platform, research collaborations involving polysaccharide and oligosaccharide interactions, and applications such as PHM23 in avian influenza research. Commercial news includes A-SUQAR®, a chewable dietary supplement containing a proprietary partially hydrolyzed guar gum formulation, along with distribution agreements and private-placement financing used for working capital and development programs.
BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotech firm, has announced that Avise Analytics has reinitiated coverage of its stock, setting a fair valuation at $2.71 per share. The report highlights Bioxytran's ProLectin-M, which shows promising recovery rates for Covid-19 patients and targets a multi-billion-dollar market. Additionally, the company is advancing BXT-25 for stroke treatment, addressing the critical treatment window challenge. Despite positive developments, funding limitations could impact drug development timelines. More details can be found in the full report.
Bioxytran, Inc. (OTCQB: BIXT) announced positive results from its Phase 2 clinical trial involving a Galectin Antagonist for treating COVID-19. The study showed complete elimination of viral load in 100% of patients by day 7, compared to only 6% in the placebo group (p=.001). Additionally, 88% reached this result by day 3. There were no serious adverse events, and no viral rebounds were observed within 14 days. The trial supports plans for a Phase 2/3 registrational study and showcases the drug's novel mechanism of action against viral entry.
Bioxytran announced that its Scientific Advisor, Prof. Avraham Mayevsky, published a book titled Cortical Spreading Depression of Leão: From Mitochondrial Function to Brain Metabolic Score. This work is linked to Bioxytran’s Hypoxia platform technology, which utilizes the MDX Viewer for measuring tissue oxygenation. The technology aims to enhance drug development by providing real-time data on oxygen consumption in tissues, potentially revolutionizing clinical trials. Bioxytran is focusing on its leading drug, ProLectin-M, targeting unmet medical needs in virology and hypoxia.
Bioxytran, a clinical stage biotechnology company, announced a peer-reviewed article supporting its oral antiviral drug, ProLectin-M, published in the International Journal of Health Sciences. The article outlines the drug's mechanism of action (MOA) as a galectin-3 antagonist, confirming initial clinical data showing viral load reduction to undetectable levels in COVID-19 patients. ProLectin-M targets the SARS-CoV-2 virus and demonstrates promising preclinical results with non-toxic levels in humans. Bioxytran aims to address significant unmet medical needs in virology.